公开(公告)号：US20210170043A1

公开(公告)日：2021-06-10

申请号：US16669291

申请日：2019-10-30

Applicant: NOVARTIS AG ,  ADURO BIOTECH, INC.

Inventor： Lisa BARNETT ,  Steven BENDER ,  Charles Y. CHO ,  Sarah COX ,  Jonathan Deane ,  Scott Martin GLASER ,  Xueshi Hao ,  Shailaja KASIBHATLA ,  Weijia OU ,  Tetsuo UNO ,  Yongqin WAN ,  Ben WEN ,  Tom Yao-Hsiang WU

IPC: A61K47/68 ,  C07K16/28 ,  A61K31/688 ,  A61P35/00

Abstract: Provided herein are immunoconjugates comprising an anti-DC-SIGN antibody conjugated to a STING agonist. Also disclosed are methods of making the immunoconjugates and methods of treating cancer using the immunoconjugates.

公开(公告)号：US12006354B2

公开(公告)日：2024-06-11

申请号：US16616318

申请日：2018-05-22

Applicant: NOVARTIS AG

Inventor： Jonathan Deane ,  Yaiza Diaz-De-Durana ,  Michael DiDonato ,  Christophe Filippi ,  Glen Spraggon

IPC: C07K14/55 ,  A61K38/20 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K16/08 ,  C07K16/10 ,  C07K19/00 ,  C12N5/071 ,  C12N5/0783 ,  A61K39/00 ,  A61K45/06

CPC classification number: C07K16/1027 ,  A61K38/2013 ,  A61K39/3955 ,  A61K47/6801 ,  A61P35/00 ,  C07K14/55 ,  C07K19/00 ,  C12N5/0636 ,  C12N5/0682 ,  A61K2039/505 ,  A61K45/06 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/94 ,  C07K2319/30

Abstract: The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and producibility over recombinant human IL2 formulations such as Proleukin®.

公开(公告)号：US20200270334A1

公开(公告)日：2020-08-27

申请号：US16616318

申请日：2018-05-22

Applicant: NOVARTIS AG

Inventor： Jonathan Deane ,  Yaiza Diaz-De-Durana ,  Michael DiDonato ,  Christophe Filippi ,  Glen Spraggon

IPC: C07K16/10 ,  C07K14/55 ,  C12N5/0783 ,  A61K39/395 ,  A61K45/06 ,  C12N5/071 ,  A61P35/00

Abstract: The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and produceability over recombinant human IL2 formulations such as Proleukin®.

公开(公告)号：US10954233B2

公开(公告)日：2021-03-23

申请号：US16330820

申请日：2017-09-06

Applicant: Novartis AG

Inventor： Phillip Alper ,  Jonathan Deane ,  Songchun Jiang ,  Tao Jiang ,  Thomas Knoepfel ,  Pierre-Yves Michellys ,  Daniel Mutnick ,  Wei Pei ,  Peter Syka ,  Guobao Zhang ,  Yi Zhang

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  A61P17/06 ,  A61P1/16 ,  A61P37/06 ,  A61P19/02 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06

Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.